Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Inclusion criteria: * Male and female ambulatory outpatients being seen in a participating physicians office for routine care, * Patients with a clinical diagnosis of COPD (all stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010) being treated with long-acting anticholinergic (Tiotropium, Spiriva® HandiHaler® ) as maintenance therapy within the product label and a maximum of the last 4 weeks (0.-28. days before Visit 1), * Patients previously treated with short-acting bronchodilators on regular or as-needed basis for at least 3 months before change to long-acting anticholinergic treatment, * Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone. Exclusion criteria: * Uncooperative patients as judged by the physician, * Patients with any conditions excluded as per Country specific package insert, * Patients currently enrolled in any clinical trial, * Patients with COPD exacerbation or any acute disease in the last 3 months before Visit 1.